Please login to the form below

Stem Cell Therapeutics

This page shows the latest Stem Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies. There is a new player on the stem cell therapy stage, thanks to $225m in start-up funding from Bayer ... BlueRock's founding and scientific investigation team

Latest news

Orphan status for Stem Cell's leukaemia drug

Tigecycline wins FDA rare disease designation. US regulators have granted orphan drug status to tigecycline, a cancer drug in development by Stem Cell Therapeutics. ... Tigecycline is being investigated by Stem Cell Therapeutics for its use in the
UK regenerative medicine projects get £8.5m boost

Novel stem cell manufacturing technologies. • Cell labelling and tracking technologies for quality control and monitoring in the body. • ... Regenerative medicine is an interdisciplinary approach that spans tissue engineering, developmental and stem
Survival strategy

Licenser/Partner. Product/Technology. Development status. Headline ($m). Mesoblast/Cephalon. Stem cell therapeutics in CHF. ... Immunotherapy company acquisition. . 428. Theramex/Teva. Branded product company acquisition. . 368. Evotec/MedImmune.
Diabetes favoured

and Oncomed's $428m strategic alliance with Bayer Schering Pharma (BSP) to discover, develop and commercialise novel anti-cancer stem cell therapeutics. ... Anti-cancer stem cell therapy platform. Discovery. 428. Ascenta Therapeutics/sanofi-aventis.
Indian stem cell companies seek UK links

Leading Indian stem cell companies are in the UK this week to seek ways to build links with the UK stem cell sector. ... Without UKTI's help, we would have had to spend a huge amount of time and expense trying to obtain all the required information on

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Deal Watch table for October 2013

Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast . ... Asset acquisition. Mesenchymal stem cell business, including Prochymal (approved). 100. †Hutchison MediPharma / Eli Lilly.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager– Medical Communications: (Negotiable - depending on experience)

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Vice President: Competitive Salary Offered

Consultant: competitive salary

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Account Director or Senior Account Director: Salary TBC

Senior Medical Writer, MedComms Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...